4//SEC Filing
Sinclair Andrew 4
Accession 0001209191-23-046096
CIK 0001720580other
Filed
Aug 15, 8:00 PM ET
Accepted
Aug 16, 6:07 PM ET
Size
27.7 KB
Accession
0001209191-23-046096
Insider Transaction Report
Form 4
Adicet Bio, Inc.ACET
Sinclair Andrew
Director
Transactions
- Award
Stock Option (Right to Buy)
2023-08-14+8,172→ 8,172 totalExercise: $2.14Exp: 2031-04-29→ Common Stock (8,172 underlying) - Award
Stock Option (Right to Buy)
2023-08-14+18,500→ 18,500 totalExercise: $2.14Exp: 2031-04-29→ Common Stock (18,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−18,500→ 0 totalExercise: $15.93Exp: 2031-04-29→ Common Stock (18,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−28,828→ 0 totalExercise: $15.75Exp: 2031-03-01→ Common Stock (28,828 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−8,172→ 0 totalExercise: $15.93Exp: 2031-04-29→ Common Stock (8,172 underlying) - Award
Stock Option (Right to Buy)
2023-08-14+26,400→ 26,400 totalExercise: $2.14Exp: 2033-05-31→ Common Stock (26,400 underlying) - Award
Stock Option (Right to Buy)
2023-08-14+28,828→ 28,828 totalExercise: $2.14Exp: 2031-03-01→ Common Stock (28,828 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−18,500→ 0 totalExercise: $11.49Exp: 2032-06-01→ Common Stock (18,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-08-14−26,400→ 0 totalExercise: $5.20Exp: 2033-05-31→ Common Stock (26,400 underlying) - Award
Stock Option (Right to Buy)
2023-08-14+18,500→ 18,500 totalExercise: $2.14Exp: 2032-06-01→ Common Stock (18,500 underlying)
Footnotes (6)
- [F1]On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F2]33% of the shares subject to this option vested and became exercisable on March 2, 2022, with the remaining 67% vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
- [F3]The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.
- [F4]The shares subject to this option are fully vested and exercisable as of the date hereof.
- [F5]The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on March 2, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
- [F6]The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
Documents
Issuer
Adicet Bio, Inc.
CIK 0001720580
Entity typeother
Related Parties
1- filerCIK 0001762451
Filing Metadata
- Form type
- 4
- Filed
- Aug 15, 8:00 PM ET
- Accepted
- Aug 16, 6:07 PM ET
- Size
- 27.7 KB